Why the study?
Does R-CHOP-14 improve survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
Does R-CHOP-14 improve survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
In patients with primary mediastinal B-cell lymphoma, R-CHOP-14 may offer better outcomes than R-CHOP-21, warranting further randomized testing.
Answers are grounded in this paper and cite their sources.
R-CHOP-14 may warrant consideration in primary mediastinal B-cell lymphoma; leaves open need for dedicated confirmatory RCTs.
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
No takes yet. Share an insight, caveat, or question.
Gleeson et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: